Compare Pinterest Inc (PINS) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pinterest Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Pinterest Inc trades at $21.11 (market cap $11.63B), while Vertex Pharmaceuticals Incorporated trades at $510.84 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 11× Pinterest Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Pinterest Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Pinterest Inc for 85 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| PINS | VRTX | |
|---|---|---|
Market Cap | $11.63B | $127.55B |
Volume | 12,792,940 | 1,487,944 |
Sector | Media | Health |
52-Week High | $35.24 | $557.96 |
52-Week Low | $15.42 | $407.37 |
Typical Hold Time | 85 Days | 120 Days |
Enterprise Value | $11.55B | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pinterest (PINS) trades at $20.31, up 1.4% today, with a bullish technical signal and strong earnings beats in recent quarters. Revenue growth accelerated to $4.22 billion in 2025, with a net income margin of 9.87%, while analyst consensus is a Buy with a $27.93 price target. Recent news highlights its undervaluation and new Visual Search Ads launch, though insider selling and cash flow volatility present mixed signals.
The outlook is positive given robust fundamentals and growth potential, but risks include competitive pressures and reliance on ad revenue. Upside is supported by earnings momentum and international monetization, yet investors should monitor cash flow trends and market sentiment shifts for sustained gains.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pinterest Inc
Pinterest is an online product and idea discovery platform that helps users gather ideas on everything from recipes to cook to destinations to travel to. Founded in 2010, the platform consists of a largely female audience, at roughly two thirds of its more than 365 million monthly active users. The company generates revenue by selling digital ads and is now rolling out more in-platform e-commerce features.
Read more on PINS →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
